oxybutynin has been researched along with Constipation in 15 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Constipation: Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The findings indicate comparability of transdermal buprenorphine and transdermal fentanyl for pain measures with significantly fewer adverse events (nausea and treatment discontinuation due to adverse events) caused by transdermal buprenorphine." | 8.88 | Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012) |
| "Combination therapy (CT) (desmopressin plus oxybutynin) has been considered for the treatment of monosymptomatic nocturnal enuresis (MNE)." | 8.31 | Combination therapy (desmopressin plus oxybutynin) improves the response rate compared with desmopressin alone in patients with monosymptomatic nocturnal enuresis and nocturnal polyuria and absence of constipation predict the response to this treatment. ( Capalbo, D; Di Sessa, A; Esposito, C; Grella, C; Guarino, S; Marzuillo, P; Miraglia Del Giudice, E; Papparella, A, 2023) |
| " Compared with other opioids, low-dose fentanyl has been suggested to produce milder side effects such as nausea, constipation, and somnolence." | 7.77 | [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]. ( Fujita, S; Fukae, M; Hata, A; Iwamori, S; Kaji, R; Katakami, N; Masuda, Y; Mifune, Y; Nanjo, S; Orita, H; Otsuka, K; Yamatani, T, 2011) |
| " Extended-release formulations of oxybutynin at 10 mg/d or tolterodine at 4 mg/d were given for 12 weeks to women with 21 to 60 urge urinary incontinence (UUI) episodes per week and an average of 10 or more voids per 24 hours." | 5.10 | Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. ( Appell, RA; Diokno, AC; Dmochowski, RR; Gburek, BM; Kell, SH; Klimberg, IW; Sand, PK, 2003) |
| "The findings indicate comparability of transdermal buprenorphine and transdermal fentanyl for pain measures with significantly fewer adverse events (nausea and treatment discontinuation due to adverse events) caused by transdermal buprenorphine." | 4.88 | Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012) |
| "Combination therapy (CT) (desmopressin plus oxybutynin) has been considered for the treatment of monosymptomatic nocturnal enuresis (MNE)." | 4.31 | Combination therapy (desmopressin plus oxybutynin) improves the response rate compared with desmopressin alone in patients with monosymptomatic nocturnal enuresis and nocturnal polyuria and absence of constipation predict the response to this treatment. ( Capalbo, D; Di Sessa, A; Esposito, C; Grella, C; Guarino, S; Marzuillo, P; Miraglia Del Giudice, E; Papparella, A, 2023) |
| " Compared with other opioids, low-dose fentanyl has been suggested to produce milder side effects such as nausea, constipation, and somnolence." | 3.77 | [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]. ( Fujita, S; Fukae, M; Hata, A; Iwamori, S; Kaji, R; Katakami, N; Masuda, Y; Mifune, Y; Nanjo, S; Orita, H; Otsuka, K; Yamatani, T, 2011) |
| "Oxybutynin was more effective for decreasing voiding frequency." | 2.80 | Transcutaneous parasacral electrical stimulation vs oxybutynin for the treatment of overactive bladder in children: a randomized clinical trial. ( Barroso Júnior, U; Bastos Netto, JM; Cunha, C; de Oliveira, LF; Lordelo, P; Moraes, M; Quintiliano, F; Veiga, ML, 2015) |
| "Daytime wetting is a common problem with various causes that can usually be identified through a careful history, thorough physical examination, and urinalysis." | 2.43 | An approach to daytime wetting in children. ( Leung, AK; Robson, WL, 2006) |
| "All medical records, including the Overactive Bladder Symptom score (OABSS), the modified Indevus Urgency Severity Scale and the International Prostate Symptoms score (IPSS) questionnaires, and uroflowmetry parameters were reviewed at each visit." | 1.48 | Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year. ( Hsiao, SM; Kuo, HC; Lin, HH, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Capalbo, D | 1 |
| Guarino, S | 1 |
| Di Sessa, A | 1 |
| Esposito, C | 1 |
| Grella, C | 1 |
| Papparella, A | 1 |
| Miraglia Del Giudice, E | 1 |
| Marzuillo, P | 1 |
| Quintiliano, F | 1 |
| Veiga, ML | 1 |
| Moraes, M | 1 |
| Cunha, C | 1 |
| de Oliveira, LF | 1 |
| Lordelo, P | 1 |
| Bastos Netto, JM | 1 |
| Barroso Júnior, U | 1 |
| Hsiao, SM | 1 |
| Lin, HH | 1 |
| Kuo, HC | 1 |
| Ellsworth, P | 1 |
| Caldamone, A | 1 |
| Saldano, DD | 1 |
| Chaviano, AH | 2 |
| Maizels, M | 2 |
| Listernick, R | 1 |
| Diokno, AC | 1 |
| Appell, RA | 1 |
| Sand, PK | 2 |
| Dmochowski, RR | 1 |
| Gburek, BM | 1 |
| Klimberg, IW | 1 |
| Kell, SH | 1 |
| Saltzstein, L | 1 |
| Robson, WL | 1 |
| Leung, AK | 1 |
| Diaz Saldano, D | 1 |
| Yerkes, EB | 1 |
| Cheng, EY | 1 |
| Losavio, J | 1 |
| Porten, SP | 1 |
| Sullivan, C | 1 |
| Zebold, KF | 1 |
| Hagerty, J | 1 |
| Kaplan, WE | 1 |
| López-Pérez, FJ | 1 |
| Mínguez-Martí, A | 1 |
| Vicario-Sánchez, E | 1 |
| Pastor-Clérigues, A | 1 |
| Sanfeliu-García, J | 1 |
| Ortega-García, MP | 1 |
| Hata, A | 1 |
| Katakami, N | 1 |
| Masuda, Y | 1 |
| Nanjo, S | 1 |
| Otsuka, K | 1 |
| Kaji, R | 1 |
| Fujita, S | 1 |
| Iwamori, S | 1 |
| Mifune, Y | 1 |
| Orita, H | 1 |
| Fukae, M | 1 |
| Yamatani, T | 1 |
| Wolff, RF | 1 |
| Aune, D | 1 |
| Truyers, C | 1 |
| Hernandez, AV | 1 |
| Misso, K | 1 |
| Riemsma, R | 1 |
| Kleijnen, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of the Efficacy and Tolerability of DITROPAN XL and DETROL LA in the Treatment of Overactive Bladder[NCT00293839] | Phase 3 | 790 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for oxybutynin and Constipation
| Article | Year |
|---|---|
Topical oxybutynin (Gelnique) for overactive bladder.
Topics: Administration, Topical; Animals; Constipation; Humans; Mandelic Acids; Randomized Controlled Trials | 2010 |
Elevating our therapeutic expectations in overactive bladder.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Constipation; Cresols; Delayed-Action Preparations; H | 2004 |
An approach to daytime wetting in children.
Topics: Arousal; Benzhydryl Compounds; Child; Child, Preschool; Constipation; Cresols; Diurnal Enuresis; Hum | 2006 |
Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain.
Topics: Administration, Oral; Analgesics, Opioid; Buprenorphine; Chronic Pain; Constipation; Fentanyl; Human | 2012 |
2 trials available for oxybutynin and Constipation
| Article | Year |
|---|---|
Transcutaneous parasacral electrical stimulation vs oxybutynin for the treatment of overactive bladder in children: a randomized clinical trial.
Topics: Child; Comorbidity; Constipation; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Tran | 2015 |
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
Topics: Administration, Oral; Aged; Benzhydryl Compounds; Constipation; Cresols; Delayed-Action Preparations | 2003 |
9 other studies available for oxybutynin and Constipation
| Article | Year |
|---|---|
Combination therapy (desmopressin plus oxybutynin) improves the response rate compared with desmopressin alone in patients with monosymptomatic nocturnal enuresis and nocturnal polyuria and absence of constipation predict the response to this treatment.
Topics: Child; Constipation; Deamino Arginine Vasopressin; Female; Humans; Male; Nocturnal Enuresis; Polyuri | 2023 |
Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Mandelic Acids; Midd | 2018 |
Pediatric voiding dysfunction: a case study.
Topics: Adolescent; Behavior Therapy; Causality; Cholinergic Antagonists; Combined Modality Therapy; Constip | 2008 |
Sustainability of remission of pediatric primary nocturnal enuresis--comparison of remission using Try for Dry vs. non-Try for Dry treatment plans.
Topics: Adolescent; Algorithms; Antidiuretic Agents; Child; Combined Modality Therapy; Constipation; Deamino | 2008 |
A thirteen-year-old girl with anemia.
Topics: Adolescent; Anemia; Chronic Disease; Constipation; Encopresis; Enuresis; Female; Humans; Mandelic Ac | 2003 |
Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.
Topics: Administration, Cutaneous; Administration, Oral; Aged, 80 and over; Chemistry, Pharmaceutical; Const | 2005 |
Office management of pediatric primary nocturnal enuresis: a comparison of physician advised and parent chosen alternative treatment outcomes.
Topics: Adolescent; Adult; Antidiuretic Agents; Child; Child, Preschool; Choice Behavior; Combined Modality | 2007 |
[Clinical experience in opioid switch for noncancer chronic pain treatment].
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Aged; Aged, 80 and over; Analgesia, Epidural; Analges | 2014 |
[Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain].
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Male; Mi | 2011 |